105 related articles for article (PubMed ID: 17634613)
21. DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer.
Germain DR; Graham K; Glubrecht DD; Hugh JC; Mackey JR; Godbout R
Breast Cancer Res Treat; 2011 May; 127(1):53-63. PubMed ID: 20499159
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive factors in early-stage breast cancer.
Cianfrocca M; Goldstein LJ
Oncologist; 2004; 9(6):606-16. PubMed ID: 15561805
[TBL] [Abstract][Full Text] [Related]
23. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
24. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study.
Dragun AE; Pan J; Rai SN; Kruse B; Jain D
Am J Clin Oncol; 2011 Jun; 34(3):231-7. PubMed ID: 20805742
[TBL] [Abstract][Full Text] [Related]
25. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
26. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
27. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
Lee JJ; Shen J
Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay.
Bièche I; Noguès C; Paradis V; Olivi M; Bedossa P; Lidereau R; Vidaud M
Clin Cancer Res; 2000 Feb; 6(2):452-9. PubMed ID: 10690523
[TBL] [Abstract][Full Text] [Related]
29. Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods.
Ambrogi F; Biganzoli E; Querzoli P; Ferretti S; Boracchi P; Alberti S; Marubini E; Nenci I
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):781-90. PubMed ID: 16467089
[TBL] [Abstract][Full Text] [Related]
30. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
31. [Modern pathologic diagnostics in breast cancer].
Szoke J; Udvarhelyi N
Orv Hetil; 2012 Jan; 153(1):22-30. PubMed ID: 22204831
[TBL] [Abstract][Full Text] [Related]
32. Population-based molecular prognosis of breast cancer by transcriptional profiling.
Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
[TBL] [Abstract][Full Text] [Related]
33. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
34. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
Saatee S; Afrakhteh M; Sadrolhefazi B
Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
[No Abstract] [Full Text] [Related]
35. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
36. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
37. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
38. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
[TBL] [Abstract][Full Text] [Related]
39. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
Sun JM; Han W; Im SA; Kim TY; Park IA; Noh DY; Heo DS; Bang YJ; Choe KJ; Kim NK
Cancer; 2004 Dec; 101(11):2516-22. PubMed ID: 15517588
[TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase-2 expression in postmastectomy chest wall relapse.
Kim JH; Bossuyt V; Ponn T; Lannin D; Haffty BG
Clin Cancer Res; 2005 Jul; 11(14):5199-205. PubMed ID: 16033837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
